Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective International Multicenter, Pivotal, Single Arm, Open Label Clinical Study to Assess the Efficacy and Safety of Intratumoral Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma

NCT05323253 is registered in ClinicalTrials.gov with Alpha Tau Medical LTD. as lead sponsor.

NCT NCT05323253
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05323253 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective International Multicenter, Pivotal, Single Arm, Open Label Clinical Study to Assess the Efficacy and Safety of Intratumoral Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma
Lead sponsor
Alpha Tau Medical LTD.
Phase
Not applicable
Overall status
Active, not recruiting
Start date
September 21, 2022
Completion date
April 30, 2027
Enrollment
86 (estimated)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent squamous cell carcinoma